Last reviewed · How we verify

Pluvicto — Competitive Intelligence Brief

Pluvicto (Pluvicto) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

marketed Prostate-specific antigen Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Pluvicto (Pluvicto) — VA Office of Research and Development.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Pluvicto TARGET Pluvicto VA Office of Research and Development marketed Prostate-specific antigen
Gallium Oxydatum GALLIUM Novartis marketed Glutamate carboxypeptidase 2, Prostate-specific antigen 2025-01-01
Pluvicto Lutetium (177Lu) vipivotide tetraxetan Aaa Usa Novartis marketed Radioligand Therapeutic Agent [EPC] Prostate-specific antigen 2022-01-01
MDV3100 mdv3100 Pfizer Inc. marketed Androgen receptor inhibitor Androgen receptor, Glucocorticoid receptor, Prostate-specific antigen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pluvicto — Competitive Intelligence Brief. https://druglandscape.com/ci/pluvicto. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: